跳轉至內容
Merck
全部照片(3)

重要文件

SAB5600047

Sigma-Aldrich

兔抗BRAF (V600E)单克隆抗体

recombinant, expressed in HEK 293 cells, clone RM8, purified immunoglobulin

同義詞:

Anti-B-RAF1, Anti-B-raf, Anti-BRAF-1, Anti-BRAF1, Anti-NS7, Anti-RAFB1

登入查看組織和合約定價


About This Item

分類程式碼代碼:
12352203
NACRES:
NA.41
暫時無法取得訂價和供貨情況

重組細胞

expressed in HEK 293 cells

品質等級

抗體表格

purified immunoglobulin

抗體產品種類

primary antibodies

無性繁殖

RM8, monoclonal
recombinant monoclonal

形狀

buffered aqueous glycerol solution

物種活性

human

濃度

~1 mg/mL

技術

ELISA: 0.5-2 μg/mL
immunoblotting: 0.5-2 μg/mL
immunocytochemistry: 0.5-5 μg/mL
immunohistochemistry: 0.5-5 μg/mL

同型

IgG

NCBI登錄號

UniProt登錄號

運輸包裝

wet ice

儲存溫度

−20°C

目標翻譯後修改

unmodified

基因資訊

human ... BRAF(673)

一般說明

BRAF(B-Raf 原癌基因)是一种丝氨酸-苏氨酸激酶,编码 B-Raf 蛋白。它位于人类染色体7q34上。

特異性

该抗体与BRAF V600E突变体反应。与野生型BRAF无交叉反应。

免疫原

对应于BRAF V600E突变体的肽

生化/生理作用

BRAF(B-Raf 原癌基因)参与细胞生长的直接信号传导。它通过在皮肤黑色素瘤、甲状腺癌和结肠癌等各种肿瘤中启动丝裂原活化蛋白激酶 (MAPK) 途径,诱导肿瘤生长。

特點和優勢

请完全放心地评估我们的抗体。如果抗体在您的研究中无效,我们将全额退款或换货。了解更多。

外觀

溶于含有50%甘油、1%BSA和0.09%叠氮化钠的磷酸盐缓冲盐水中。

免責聲明

除非我们的产品目录或产品附带的其他公司文档另有说明,否则我们的产品仅供研究使用,不得用于任何其他目的,包括但不限于未经授权的商业用途、体外诊断用途、离体或体内治疗用途或任何类型的消费或应用于人类或动物。

未找到適合的產品?  

試用我們的產品選擇工具.

儲存類別代碼

10 - Combustible liquids

水污染物質分類(WGK)

WGK 2

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

未看到正確版本?

如果您需要一個特定的版本,您可以透過批號來尋找特定憑證。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Xuhong Wang et al.
Oncology letters, 18(1), 927-935 (2019-07-11)
Keratin 19 (KRT19) is a type I cytokeratin that serves an important role in multiple types of cancer; however, little is known regarding its role in thyroid cancer. Therefore, the aim of the current study was to investigate the role
The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases: The implications for BRAF inhibitor therapy.
Hannan EJ, et al.
Medicine, 96(48), e8404-e8404 (2017)
Maria Russi et al.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 180, 106311-106311 (2022-10-24)
Two clinically approved anticancer drugs targeting BRAF in melanoma patients - dabrafenib (DAB) and vemurafenib (VEM) - have been successfully encapsulated into nanomicelles formed upon self-assembly of an amphiphilic dendrimer AD based on two C18 aliphatic chains and a G2
Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study.
Shinozaki E, et al.
British Journal of Cancer, 117(10), 1450-1450 (2017)
Daniel Delev et al.
Scientific reports, 10(1), 96-96 (2020-01-11)
Long-term epilepsy-associated tumors (LEATs) represent mostly benign brain tumors associated with drug-resistant epilepsy. The aim of the study was to investigate the specific transcriptional signatures of those tumors and characterize their underlying oncogenic drivers. A cluster analysis of 65 transcriptome

Questions

Reviews

No rating value

Active Filters

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務